The Non-Small Cell Lung Cancer Market to Grow With Increase in Prevalence of Non-Small Cell Lung Cancer

 

Non-Small Cell Lung Cancer Market

Global Non-Small Cell Lung Cancer Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large-cell Carcinoma, and Large-cell Neuroendocrine Tumors), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Others), By End User (Hospitals, Homecare, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2023-2030

Global Non-Small Cell Lung Cancer Market is estimated to be valued at US$ 24,910.7 million in 2022 and is expected to exhibit a CAGR of 9.4% during the forecast period (2022-2030).

Market Overview:

Non-Small Cell Lung Cancer (NSCLC) is the disease in which malignant (cancer) cells form in the tissues of the lung. It is the most common type of lung cancer. It is curable, especially with early detection and treatment. Certain factors can affect overall prognosis, such as the stage of the cancer and the size of the tumor. The main difference between small cell lung cancer (SCLC) and NSCLC is how aggressive they are. Non-small cell lung cancer is a less aggressive and more common form of lung cancer compared to SCLC. NSCLC can progress quickly, though not as quickly as SCLC. Another difference is how common they are. There are several types of NSCLC. Smoking is the major risk factor for non-small cell lung cancer.

Competitive Landscape:

Major players operating in the global Non-Small Cell Lung Cancer Market t are Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Merck, Takeda Pharmaceuticals, Eli Lilly and Company, Pfizer, Novartis, F. Hoffmann-La Roche, and Bayer Healthcare.

Key Market Drivers:

Increase in prevalence of non-small cell lung cancer across the globe is expected to boost growth of the global Non-Small Cell Lung Cancer Market during the forecast period. For instance, the burden of NSCLC is increasing majorly due to the growing number of people with unhealthy habits such as tobacco and alcohol consumption, smoking, sedentary lifestyle, and high dose of supplements. According to World Health Organization (WHO), February 2022 report, over 2.2 million people were diagnosed with lung cancer in 2020, and non-small cell lung cancer (NSCLC) accounted for nearly 85% of the share of all lung cancer patients.

Moreover, increase in demand for safe and effective treatment is expected to boost the growth of the non-small cell lung cancer market. For instance, in August 2022, the U.S. Food and Drug Administration (USFDA) approved capmatinib (Tabrecta, Novartis Pharmaceuticals Corporation) for adult patients with metastatic NSCLC whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.

COVID-19 Impact Analysis:

People with Non-Small Cell Lung Cancer (NSCLC) may have an increased risk of severe illness from COVID-19. Thus, the guidelines advice people to follow the protocols to protect themselves from COVID-19 while maintaining their treatment schedule and getting the vaccine when their doctor advises. If people with non-small cell lung cancer (NSCLC) gets COVID-19 infection, they may be at higher risk of severe complications. This in turn is expected to increase demand for safe and effective treatment worldwide, driving the market growth.

Key Takeaways:

·       The Non-Small Cell Lung Cancer Market is expected to exhibit a CAGR of XX % during the forecast period due to the introduction of novel drugs or increase in new drug approvals. For instance, in October 2021, the U.S. FDA approved Genentech, Inc.’s atezolizumab (Tecentriq) for stage II and IIIA non-small cell lung cancer patients.

·       Among regions, North America is expected to witness robust growth in the non-small cell lung cancer market owing to the increase in burden of NSCLC, increase in demand for safe/effective treatment, increase in awareness among people, well-established healthcare infrastructure, and high diagnosis and treatment rates in the region.

For instance, about 10% to 15% of all lung cancers are small cell lung cancer, and about 80% to 85% are non-small cell lung cancer. According to the American Cancer Society (ACS), in 2023, there will be around 238,340 new cases of lung cancer cases diagnosed and over 127,070 cancer deaths in the United States.

Moreover, in May 2021, the U.S. FDA approved Lumakras (Sotorasib) as the first treatment for adult patients with NSCLC whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.